diclofenac has been researched along with bufuralol in 18 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (5.56) | 18.2507 |
2000's | 10 (55.56) | 29.6817 |
2010's | 6 (33.33) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Caradonna, NP; Hallifax, D; Houston, JB; Turlizzi, E; Zanelli, U | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Kanebratt, KP; Sjögren, E; Svanberg, P | 1 |
Chen, L; Fei, J; Mei, Y; Ren, S; Yan, SF; Zeng, J; Zhang, JZ | 1 |
Bonnabry, P; Dayer, P; Leemann, T | 1 |
Ekins, S; Lawton, MP; Mankowski, DC | 1 |
Fujita, K; Kamataki, T; Nakayama, K; Nohmi, T; Tsuruma, K; Yamada, M; Yamazaki, Y | 1 |
Chiba, K; Kobayashi, K; Shimada, N; Urashima, K | 1 |
Beattie, IG; Graham, KS; Riley, RJ; Weaver, R | 1 |
DeSante, KA; Gillespie, JS; Jensen, CB; Long, AJ; Petullo, D; Read, HA; Ring, B; Sanburn, NP; Sauer, JM; Smith, BP; VandenBranden, MR; Witcher, JW; Wrighton, SA | 1 |
Ekman, S; Fransson-Steen, R; Hagbjörk, AL; Löfgren, S; Terelius, Y | 1 |
Carter, GT; Di, L; Kerns, EH; Li, SQ | 1 |
Hall, SD; Harrelson, JP; Mao, J; Mohutsky, MA; Wrighton, SA | 1 |
Andersson, TB; Artursson, P; Christensen, H; Krogstad, V; Matsson, P; Urdzik, J; Wegler, C | 1 |
18 other study(ies) available for diclofenac and bufuralol
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs.
Topics: Cell Line, Tumor; Cryopreservation; Female; Hepatocytes; Humans; Male; Metabolic Clearance Rate; Pharmaceutical Preparations; Predictive Value of Tests | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Optimized experimental design for the estimation of enzyme kinetic parameters: an experimental evaluation.
Topics: Chromatography, Liquid; Cytochrome P-450 Enzyme System; Humans; Kinetics; Microsomes, Liver; Research Design; Tandem Mass Spectrometry | 2012 |
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kinetics; Microsomes, Liver; Models, Molecular; Molecular Dynamics Simulation; Substrate Specificity | 2013 |
Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Topics: Carbon Monoxide; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; Ethanolamines; Humans; Microsomes, Liver; Midazolam; Mixed Function Oxygenases; Oxidoreductases, O-Demethylating | 1994 |
Characterization of transgenic mouse strains using six human hepatic cytochrome P450 probe substrates.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; Ethanolamines; Humans; Intestines; Mephenytoin; Mice; Mice, Inbred C57BL; Mice, Obese; Mice, Transgenic; Microsomes; Microsomes, Liver; Mixed Function Oxygenases; Phenacetin; Recombinant Proteins; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Substrate Specificity; Testosterone | 2000 |
Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Topics: Alkylating Agents; Aryl Hydrocarbon Hydroxylases; Coumarins; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diclofenac; Ethanolamines; Genetic Engineering; Humans; Midazolam; Mixed Function Oxygenases; Mutagenicity Tests; NADP; NADPH-Ferrihemoprotein Reductase; Nitrosamines; Recombinant Proteins; Salmonella typhimurium; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases | 2001 |
Substrate specificity for rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems of the rat.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Baculoviridae; Cells, Cultured; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Gene Expression; Humans; Insecta; Isoenzymes; Mephenytoin; Midazolam; Nitrophenols; Pharmaceutical Preparations; Phenacetin; Rats; Substrate Specificity; Testosterone; Tumor Cells, Cultured | 2002 |
Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Design; Drug Industry; Drug Interactions; Drugs, Investigational; Escherichia coli; Ethanolamines; Evaluation Studies as Topic; Kinetics; Mass Spectrometry; Mephenytoin; Microsomes, Liver; Midazolam; Molecular Probes; Phenacetin; Recombinant Proteins; Substrate Specificity | 2003 |
Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
Topics: Aryl Hydrocarbon Hydroxylases; Atomoxetine Hydrochloride; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Diclofenac; Drug Interactions; Ethanolamines; Humans; Hydroxylation; Microsomes, Liver; Midazolam; Phenacetin; Propylamines | 2004 |
Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison.
Topics: Amiodarone; Animals; Aryl Hydrocarbon Hydroxylases; Blotting, Western; Chlorzoxazone; Coumarins; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2B6; Cytochrome P-450 Enzyme System; Dextromethorphan; Diclofenac; DNA, Complementary; Ethanolamines; Female; Humans; Kinetics; Lauric Acids; Male; Mephenytoin; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Microsomes, Liver; Mixed Function Oxygenases; NADP; Nitrophenols; Oxidoreductases, N-Demethylating; Oxygen; Paclitaxel; Phenacetin; Rats; Sex Factors; Species Specificity; Substrate Specificity; Testosterone | 2004 |
Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS.
Topics: Aryl Hydrocarbon Hydroxylases; Chromatography, High Pressure Liquid; Coumarins; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Drug Design; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Fluorescent Dyes; Humans; In Vitro Techniques; Isoenzymes; Kinetics; Liver; Microsomes, Liver; Midazolam; Recombinant Proteins; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Substrate Specificity; Tandem Mass Spectrometry | 2007 |
Predictions of cytochrome P450-mediated drug-drug interactions using cryopreserved human hepatocytes: comparison of plasma and protein-free media incubation conditions.
Topics: Aryl Hydrocarbon Hydroxylases; Cell Culture Techniques; Cells, Cultured; Chromatography, High Pressure Liquid; Cryopreservation; Culture Media; Culture Media, Serum-Free; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diclofenac; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Hepatocytes; Humans; Hydroxylation; Midazolam; Plasma; Predictive Value of Tests; Substrate Specificity; Tandem Mass Spectrometry | 2012 |
Influence of Proteome Profiles and Intracellular Drug Exposure on Differences in CYP Activity in Donor-Matched Human Liver Microsomes and Hepatocytes.
Topics: Bupropion; Cytochrome P-450 Enzyme System; Diclofenac; Drug Evaluation, Preclinical; Ethanolamines; Hepatobiliary Elimination; Hepatocytes; Humans; Liver; Microsomes, Liver; Midazolam; Omeprazole; Proteome; Proteomics | 2021 |